Intersect Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $2.13M | Buy |
27,671
+5,432
| +24% | +$414K | 0.64% | 29 |
|
|
2022
Q1 | $1.62M | Buy |
22,239
+4,216
| +23% | +$283K | 0.31% | 61 |
|
|
2021
Q4 | $1.12M | Buy |
18,023
+6,063
| +51% | +$356K | 0.21% | 97 |
|
|
2021
Q3 | $708K | Sell |
11,960
-844
| -7% | -$55.6K | 0.12% | 133 |
|
|
2021
Q2 | $856K | Sell |
12,804
-75
| -0.6% | -$4.89K | 0.15% | 113 |
|
|
2021
Q1 | $813K | Sell |
12,879
-810
| -6% | -$50.4K | 0.16% | 103 |
|
|
2020
Q4 | $849K | Buy |
13,689
+1,747
| +15% | +$107K | 0.19% | 88 |
|
|
2020
Q3 | $720K | Sell |
11,942
-501
| -4% | -$30.2K | 0.19% | 88 |
|
|
2020
Q2 | $732K | Buy |
12,443
+2,179
| +21% | +$130K | 0.24% | 70 |
|
|
2020
Q1 | $572K | Buy |
10,264
+1,367
| +15% | +$83.6K | 0.23% | 77 |
|
|
2019
Q4 | $571K | Buy |
8,897
+1,283
| +17% | +$73.5K | 0.19% | 88 |
|
|
2019
Q3 | $386K | Sell |
7,614
-113
| -1% | -$5.31K | 0.14% | 116 |
|
|
2019
Q2 | $350K | Sell |
7,727
-119
| -2% | -$5.54K | 0.14% | 119 |
|
|
2019
Q1 | $374K | Buy |
7,846
+446
| +6% | +$22.2K | 0.16% | 100 |
|
|
2018
Q4 | $385K | Sell |
7,400
-159
| -2% | -$8.54K | 0.18% | 85 |
|
|
2018
Q3 | $469K | Sell |
7,559
-771
| -9% | -$45.8K | 0.2% | 80 |
|
|
2018
Q2 | $461K | Sell |
8,330
-2,230
| -21% | -$120K | 0.22% | 75 |
|
|
2018
Q1 | $668K | Buy |
10,560
+3
| +0% | +$193 | 0.35% | 57 |
|
|
2017
Q4 | $647K | Sell |
10,557
-982
| -9% | -$61.4K | 0.35% | 58 |
|
|
2017
Q3 | $735K | Sell |
11,539
-190
| -2% | -$11.1K | 0.42% | 52 |
|
|
2017
Q2 | $654K | Buy |
11,729
+919
| +9% | +$50K | 0.39% | 54 |
|
|
2017
Q1 | $588K | Sell |
10,810
-4,545
| -30% | -$249K | 0.51% | 46 |
|
|
2016
Q4 | $897K | Sell |
15,355
-3,290
| -18% | -$180K | 0.67% | 36 |
|
|
2016
Q3 | $1M | Buy |
18,645
+8,493
| +84% | +$546K | 0.79% | 32 |
|
|
2016
Q2 | $747K | Buy |
10,152
+156
| +2% | +$11K | 0.45% | 49 |
|
|
2016
Q1 | $639K | Buy |
9,996
+234
| +2% | +$14.8K | 0.4% | 51 |
|
|
2015
Q4 | $672K | Sell |
9,762
-7
| -0.1% | -$463 | 0.58% | 40 |
|
|
2015
Q3 | $578K | Sell |
9,769
-2,449
| -20% | -$155K | 0.53% | 46 |
|
|
2015
Q2 | $813K | Sell |
12,218
-256
| -2% | -$16.9K | 0.69% | 38 |
|
|
2015
Q1 | $795K | Buy |
12,474
+2,436
| +24% | +$153K | 0.61% | 38 |
|
|
2014
Q4 | $593K | Buy |
+10,038
| New | +$566K | 0.5% | 42 |
|
Other funds holding BMY
Intersect Capital's BMY Position: Q2 2022 in Review
Intersect Capital increased its Bristol-Myers Squibb (BMY) stake by 24% in Q2 2022, buying an estimated $414K and bringing the position to 27,671 shares worth $2.13M. The position accounts for 0.64% of the portfolio, ranked #29.
Intersect Capital first reported a position in BMY in Q4 2014 and has held it in 31 quarters since. 2,538 funds tracked by Wall St. Rank hold BMY as of Q2 2022.
- Intersect Capital held 27,671 shares of Bristol-Myers Squibb worth $2.13M as of Q2 2022.
- Intersect Capital bought 5,432 Bristol-Myers Squibb shares in Q2 2022, an estimated $414K.
- Bristol-Myers Squibb made up 0.64% of Intersect Capital's portfolio in Q2 2022, its #29 holding.
- Intersect Capital first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 31 quarters since.
- 2,538 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.
Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.